The global market size for hyaluronidase is forecasted to grow at a CAGR of 9.04% from 2024 to 2029 and be worth USD 1578.2 million by 2029 from USD 1023.8 million in 2024.
Hyaluronidase is an injectable enzyme solution that aids in the natural decomposition of hyaluronic acid. Local anesthetics, chemotherapeutics, and contrast media have all been utilized as spreading agents with these enzymes. When a drug cannot be injected into a vein, it is mixed with other drugs and injected under the skin to improve absorption by the body. It also helps radioactive chemicals absorb better during subcutaneous urography. Hyaluronidase is used in combination with fluid injections to treat dehydration. It's also used to aid the body's absorption of other drugs injected into the body. Hyaluronidase can also help contrast dyes in the body show up more clearly on some scans or X-rays. Hyaluronidases are a type of enzyme that can be found in various venoms and toxins.
The growing awareness of the importance of changing one's physical appearance has resulted in a surge in demand for cosmetic and aesthetic procedures. The rising prevalence of skin problems and the easy availability of advanced aesthetic treatments drive the market for hyaluronidase in cosmetic dermatology. In addition, using enzyme-based substrates for noninvasive tumor imaging in cancer metastasis and multiple applications in cancer therapy, aesthetic treatments, and ophthalmic therapeutic solutions are essential to market drivers. Cancer has become the second biggest cause of mortality worldwide, after cardiovascular diseases. This phenomenon is caused by environmental variables such as shifting dietary trends, urbanization, and a longer post-reproductive lifespan. As a result, the rising occurrence of cancer boosts market growth.
Furthermore, the growing senior population, favorable payment policies, and growing number of patients choosing nonsurgical procedures further accelerate market growth. In addition, rapid technological advancements in healthcare are increasing R&D, and hyaluronidase-based medicines are readily available in hospitals and medical stores, all of which are likely to create new opportunities that will impact the growth of the hyaluronidase market in the forecast period. The practitioner/beautician must be well-versed in the proper dosage of hyaluronidase and any potential problems and necessary treatments. Rising innovations aimed at lowering the negative effects of hyaluronidase administration are projected to provide profitable opportunities for key companies in the market.
The various side effects of the product on the human body and the high expenditure involved in research and development are expected to act as significant restraints on the growth of the global hyaluronidase market. Skin rashes, irregular heartbeats, dizziness, and unusual weakness are expected to hamper the market in the near future. A lack of awareness may challenge the market's growth during the forecast period.
During the forecast period, however, the outbreak of the COVID-19 pandemic will impact market growth. The worldwide travel prohibition will impact medical tourism in emerging economies, which is dependent on cosmetic surgical treatments. The COVID-19 pandemic has touched practically every element of cancer care and research, from bringing new hazards for cancer patients to disrupting cancer treatment delivery and research continuity. COVID-19 has complicated cancer patient treatment, but it has also spurred creative solutions to clinical care challenges. Research into the new disease benefits from insights gained over years of cancer research. This aspect will limit the market's growth over the forecast period. Furthermore, disruptions in the supply chain and a lower rate of procedure adoption are projected to slow the market for hyaluronidase in the short term. The demand for cosmetics and aesthetic services has increased as people have become more conscious of their appearance. The rise in demand for hyaluronidase power injections among cosmetologists and dermatologists is expected to drive hyaluronidase demand in the global market.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 to 2029 |
|
Base Year |
2023 |
|
Forecast Period |
2024 to 2029 |
|
Segments Covered |
By Type, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
|
Key Market Players |
Amphastar Pharmaceuticals Inc., Halozyme Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., Shreya Life Sciences Pvt. Ltd. and Calzyme |
The animal-derived hyaluronidase segment had the most significant share of the market in 2023. Most approved and commercialized brands are now sourced from animal sources; thus, it is likely to keep their dominance throughout the forecast period. Furthermore, recombinant human hyaluronidase has been shown in several investigations to improve the quality and safety of local anesthetic blocks. In addition, the absorption of other injectable fluids in the body is likely to be aided by animal-derived Hyaluronidase, making the treatment process less dangerous. As a result of these considerations, animal-derived hyaluronidase is predicted to grow in popularity over the forecast period.
The dermatology segment is expected to dominate the worldwide hyaluronidase market during the forecast period. The hyaluronidase enzyme aids in the diffusion and absorption of injected fluids in the tissues. It also improves the effectiveness of local anesthetics and reduces the danger of necrosis.
To manage hyaluronic acid injection problems efficiently, clinicians must be well-informed of their symptoms. In addition, it is critical to have good action plans for emergencies in which the needed agents are readily available at the operation or treatment site.
The hyaluronidase market in North America was the largest worldwide in 2023. Because of key firms manufacturing these drugs, the high acceptance of innovative treatment alternatives, and the large number of dermatological clinics prescribing such therapies, North America is likely to hold a significant share in the global hyaluronidase market during the forecast period. Furthermore, rising healthcare spending and well-established healthcare infrastructure contribute to the overall regional market's growth. The United States plays a crucial role in North America's geographic contribution to the worldwide hyaluronidase market, owing to the increasing adoption of facial aesthetic procedures and the desire for minimally invasive cosmetic procedures.
Due to medical tourism in dermatology and chemotherapy in many nations, Asia Pacific will witness the most significant rise. Many worldwide corporations have begun to invest in the Asia-Pacific region. The Asian market has risen quickly due to many providers and advancements in technology. South Korea is second only to China in terms of income generation. Alteogen copyrighted its protein engineering technology after developing the world's second human recombinant hyaluronidase (recombinant) protein.
Amphastar Pharmaceuticals Inc., Halozyme Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., Shreya Life Sciences Pvt. Ltd. and Calzyme are some of the noteworthy companies operating in the global hyaluronidase market profiled in this report.
By Type
By Application
By End-User
By Region
Frequently Asked Questions
The global hyaluronidase market size is expected to be worth USD 939.2 million in 2023.
The growing demand for hyaluronidase in cancer treatment, the growing prevalence of chronic diseases, and the rising demand for minimally invasive procedures majorly drive the growth of the market.
Halozyme Therapeutics, Inc., Pfizer, Inc., Shire plc, and Baxter International Inc. are some of the noteworthy companies in the market.
The future of the hyaluronidase market looks promising, with continued growth expected in the coming years. The increasing demand for hyaluronidase in cancer treatment and the growing focus on minimally invasive procedures are expected to drive the growth of this market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region